IDP 602
Alternative Names: IDP-602Latest Information Update: 04 Apr 2023
Price :
$50 *
At a glance
- Originator IDP Pharma
- Class Eye disorder therapies; Peptides
- Mechanism of Action Hypoxia inducible factor 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Eye disorders
Most Recent Events
- 30 Mar 2023 IDP 602 is available for licensing as of 30 Mar 2023. https://www.idp-pharma.com/partnerships%ef%bb%bf-collaborations/
- 04 Jan 2023 IDP Pharma signs a license option agreement with a USA based Biotech for IDP 602 (IDP Pharma pipeline, March 2023)
- 04 Jan 2023 Preclinical trials in Eye disorders in Spain (Ophthalmic), prior to January 2023 (IDP Pharma pipeline, March 2023)